BHC Bausch Health Companies Inc.

28.95
+0.27  (+1%)
Previous Close 28.68
Open 28.7
Price To Book 4.11
Market Cap 10,198,145,428
Shares 349,757,253
Volume 3,514,235
Short Ratio 2.35
Av. Daily Volume 4,118,452
Stock charts supplied by TradingView

NewsSee all news

  1. Bausch + Lomb And TerraCycle Announce Donation Of New Custom Training Modules Incorporating Used Contact Lens Materials To Guide Dog Foundation

    Benches, Tables, Waste Stations and an Agility Ramp Will Help  Train Guide Dogs for the Blind or Visually Impaired BRIDGEWATER, N.J., Nov. 13, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye

  2. Bausch Health Companies Announces Participation in Upcoming Investor Conferences

    LAVAL, Quebec, Nov. 11, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) today announced that the Company will participate in three investor conferences. Joseph C. Papa, chairman and chief executive officer,

  3. Bausch Health Companies Inc. Announces Third-Quarter 2019 Results and Raises Full-Year Revenue and Adjusted EBITDA (non-GAAP) Guidance Ranges

    LAVAL, Quebec, Nov. 4, 2019 /PRNewswire/ -- Third-Quarter 2019 Financial Results Revenues of $2.209 Billion GAAP Net Loss of $49 Million Adjusted EBITDA (non-GAAP)1 of $942 Million GAAP Cash Generated from Operations of

  4. Salix Announces Issuance of an Additional XIFAXAN® Patent

    LAVAL, Quebec, Oct. 31, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of

  5. Salix Pharmaceuticals Announces Inaugural Scholarship Program To Commemorate Its 30th Anniversary

    Applications For The Salix Gastrointestinal Health Scholars Program Will Be Accepted Beginning Nov. 1, 2019 BRIDGEWATER, N.J., Oct. 30, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) and its

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approval announced May 7, 2018.
Plenvu (NER1006)
Bowel cleansing
Approval announced November 2, 2017.
Latanoprostene bunod
Open angle glaucoma (OAG) or ocular hypertension (OHT)
FDA approval announced February 25, 2019.
Loteprednol Gel 0.38%
Ocular Inflammation
Approval announced December 22, 2017.
LUMIFY (brimonidine tartrate ophthalmic solution 0.025%)
Eye Brightener
FDA Approval announced August 24, 2018.
IDP-121
Acne
Tentative FDA Approval announced October 8, 2018. Final approval expected November 2018 pending the expiration of exclusivity for a related product.
IDP-122
Psoriasis
Phase 3 trial ongoing.
IDP-120
Acne
FDA approval announced April 25, 2019.
DUOBRII (halobetasol propionate and tazarotene)
Psoriasis
PDUFA date December 22, 2019.
IDP-123
Psoriasis
Approved February 15, 2017.
Brodalumab
Psoriasis
CRL received October 18, 2019. To resubmit in 2Q 2020.
Suprachoroidal CLS-TA - PEACHTREE
Macular edema associated with non-infectious uveitis
Approval announced March 2, 2018.
ULTRA - 7 days
Contact lens
CRL issued July 12, 2019. NDA to be resubmitted in December 2019.
EM-100
Allergic conjunctivitis
Phase 2 interim analysis due 1Q 2020.
Rifaximin
Overt hepatic encephalopathy
Phase 3 trial ongoing.
IDP-124
Atopic Dermatitis

Latest News

  1. Bausch + Lomb And TerraCycle Announce Donation Of New Custom Training Modules Incorporating Used Contact Lens Materials To Guide Dog Foundation

    Benches, Tables, Waste Stations and an Agility Ramp Will Help  Train Guide Dogs for the Blind or Visually Impaired BRIDGEWATER, N.J., Nov. 13, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye

  2. Bausch Health Companies Announces Participation in Upcoming Investor Conferences

    LAVAL, Quebec, Nov. 11, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) today announced that the Company will participate in three investor conferences. Joseph C. Papa, chairman and chief executive officer,

  3. Bausch Health Companies Inc. Announces Third-Quarter 2019 Results and Raises Full-Year Revenue and Adjusted EBITDA (non-GAAP) Guidance Ranges

    LAVAL, Quebec, Nov. 4, 2019 /PRNewswire/ -- Third-Quarter 2019 Financial Results Revenues of $2.209 Billion GAAP Net Loss of $49 Million Adjusted EBITDA (non-GAAP)1 of $942 Million GAAP Cash Generated from Operations of

  4. Salix Announces Issuance of an Additional XIFAXAN® Patent

    LAVAL, Quebec, Oct. 31, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of

  5. Salix Pharmaceuticals Announces Inaugural Scholarship Program To Commemorate Its 30th Anniversary

    Applications For The Salix Gastrointestinal Health Scholars Program Will Be Accepted Beginning Nov. 1, 2019 BRIDGEWATER, N.J., Oct. 30, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) and its

  6. Salix Pharmaceuticals to Present New Clinical Data at the American College of Gastroenterology (ACG) Annual Meeting

    TRULANCE® (plecanatide) Poster Presentation Recognized with Presidential Poster Award Distinction BRIDGEWATER, N.J., Oct. 28, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) and its gastroenterology

  7. Bausch + Lomb Introduces PreserVision® AREDS 2 Formula Minigel Eye Vitamins

    Now Available at Major U.S. Retailers BRIDGEWATER, N.J., Oct. 21, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TXS: BHC),

  8. Bausch Health's Ortho Dermatologics Business To Present Data At The Fall Clinical Dermatology Conference

    18 Poster Presentations on Investigational and Existing Products LAVAL, Quebec, Oct. 15, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) and its dermatology business, Ortho Dermatologics, one of the largest

  9. Ortho Dermatologics Announces 2019 Aspire Higher Scholarship Recipients

    $10,000 Scholarships Awarded to Nine Students Affected by Dermatologic Conditions LAVAL, Quebec, Oct. 10, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) and its dermatology business, Ortho Dermatologics,

  10. Bausch + Lomb Announces New Scientific And Clinical Analyses To Be Presented During The American Academy Of Ophthalmology And American Academy Of Optometry Annual Meetings

    BRIDGEWATER, N.J., Oct. 7, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TXS: BHC), today announced that 14 new scientific

  11. Bausch Health Companies Inc. Will Release Third-Quarter 2019 Financial Results on November 4

    LAVAL, Quebec, Oct. 4, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health") will release its third-quarter 2019 financial results on Monday, Nov. 4, 2019. Bausch Health will host a

  12. Bausch Health Files Lawsuit Against Sandoz For Infringement Of Patents Protecting XIFAXAN® 550 mg Tablets

    BRIDGEWATER, N.J., Oct. 1, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") along with its wholly owned subsidiary, Salix Pharmaceuticals ("Salix"),

  13. Bausch Health Releases 2018 Corporate Social Responsibility Report

    Second Annual Report Reinforces the Company's Continued Commitment to Responsible, Ethical and Sustainable Operations LAVAL, Quebec, Sept. 10, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC)

  14. Bausch Health To Reduce Debt By Approximately $200 Million Using Cash Flow From Operations

    LAVAL, Quebec, Sept. 3, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health" or the "Company") today announced it will reduce debt by approximately $200 million through the

  15. Bausch Health Companies Announces Participation In Upcoming Investor Conferences

    LAVAL, Quebec, Aug. 29, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) today announced that the Company will participate in three investor conferences. Paul S. Herendeen, executive vice president and chief